Product image of Lamivudine/Zidovudine Mylan (Zidovudine, Lamivudine) supplied by GNH India

Lamivudine/Zidovudine Mylan

Active Ingredient:
Zidovudine, Lamivudine
Origin:
EU

Lamivudine/Zidovudine Mylan (Zidovudine, Lamivudine)

Lamivudine and Zidovudine, the active ingredients in Lamivudine/Zidovudine Mylan, are nucleoside reverse transcriptase inhibitors presented as oral tablets (strength unspecified) for oral use. These agents are part of combination regimens that are standard of care for managing chronic HIV infection.

GNH India supplies Lamivudine/Zidovudine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our network ensures reliable delivery and regulatory compliance across multiple regions.

Manufacturer / TM Owner

Mylan Pharmaceuticals Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lamivudine/Zidovudine is a nucleoside reverse transcriptase inhibitor used in the management of HIV infection.

  • HIV-1 infection (adults): reduces viral replication, improves CD4+ T‑cell counts, and delays disease progression when used as part of combination antiretroviral therapy.
  • HIV-1 infection (children): forms part of combination antiretroviral therapy to control viral load and support immune development in pediatric patients.
  • HIV-1 infection (pregnant women): used with other agents to lower the risk of mother‑to‑child transmission while maintaining maternal health.

How It Works

  • Lamivudine and Zidovudine are nucleoside analogues that, after intracellular phosphorylation, compete with natural nucleosides for incorporation into viral DNA by HIV reverse transcriptase. Their incorporation results in premature chain termination, halting synthesis of proviral DNA and thereby suppressing viral replication. This mechanism is independent of the virus’s entry or integration steps, focusing solely on the reverse transcription phase.

Side Effects

Lamivudine/Zidovudine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: transient cranial discomfort.
  • Fatigue: general tiredness or weakness.
  • Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects

  • Lactic acidosis: severe metabolic disturbance requiring immediate medical attention.
  • Hepatic steatosis: accumulation of fat in the liver that can progress to liver failure.
  • Bone marrow suppression: anemia, neutropenia, or thrombocytopenia.
  • Hypersensitivity reactions: rash, fever, or Stevens‑Johnson syndrome.

Precautions & Warnings

Before initiating Lamivudine/Zidovudine therapy, clinicians should consider several precautionary measures to ensure patient safety.

  • Monitor blood counts: perform baseline and periodic CBC to detect anemia or neutropenia.
  • Assess liver function: check transaminases regularly due to risk of hepatic toxicity.
  • Evaluate hypersensitivity: discontinue if rash, fever, or severe skin reactions develop.
  • Adjust for renal impairment: dose may need modification in patients with reduced kidney function.
  • Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Lamivudine/Zidovudine can interact with other medicines, affecting efficacy or toxicity.

Major Interactions (Avoid)

  • Didanosine: concurrent use increases risk of pancreatitis; avoid co‑administration.
  • Stavudine: combined therapy heightens mitochondrial toxicity; avoid together.
  • Alcohol: may exacerbate hepatic side effects and lactic acidosis; avoid.

Moderate Interactions (Monitor Closely)

  • Efavirenz: may raise zidovudine plasma concentrations; monitor therapeutic levels.
  • Ritonavir‑boosted protease inhibitors: can alter zidovudine metabolism; adjust dose if needed.
  • Nephrotoxic agents: concurrent use may worsen renal function; monitor kidney parameters.

Frequently Asked Questions

Lamivudine/Zidovudine is prescribed as part of combination antiretroviral therapy to treat HIV-1 infection. It helps suppress viral replication, improve immune function, and reduce the risk of disease progression in adults, children, and pregnant women when used with other approved HIV medicines.

Both lamivudine and zidovudine are nucleoside analogues that, after being phosphorylated inside cells, mimic natural nucleosides. When HIV reverse transcriptase incorporates them into viral DNA, the chain is terminated prematurely, preventing the virus from completing its replication cycle.

The appropriate dose of Lamivudine/Zidovudine is individualized by the prescribing clinician based on factors such as patient age, weight, renal function, and the specific antiretroviral regimen. No fixed dosing schedule is provided here; the prescriber sets the regimen.

Data on lamivudine and zidovudine use during pregnancy and lactation are limited. The drugs may be used when the potential benefit to the mother outweighs potential risks to the fetus or infant. Decisions should be made by a qualified healthcare professional.

To request Lamivudine/Zidovudine, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine/Zidovudine is a dual NRTI combination that offers potent viral suppression but may have a higher risk of mitochondrial toxicity compared with newer agents such as tenofovir/emtricitabine. Choice of regimen depends on resistance patterns, patient comorbidities, and tolerability considerations.

Store the tablets at ambient temperature below 25 °C, in the original container, protected from moisture and direct sunlight. Do not refrigerate or freeze. Keep out of reach of children and follow any additional instructions on the packaging.

Lamivudine/Zidovudine is taken orally, usually as a tablet, with a full glass of water. It may be taken with or without food, but consistency with respect to meals helps maintain stable drug levels. Swallow the tablet whole; do not crush or chew unless instructed by a pharmacist.

Serious adverse events include lactic acidosis, severe hepatic steatosis, bone marrow suppression (anemia, neutropenia, thrombocytopenia), and hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of these conditions, and therapy should be stopped immediately if they occur.

Lamivudine/Zidovudine should be avoided in individuals with known hypersensitivity to either component, those with severe anemia or neutropenia, and patients with significant hepatic impairment unless benefits outweigh risks. Clinicians should also exercise caution in patients with renal dysfunction and adjust therapy accordingly.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Zidovudine, Lamivudine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT